Cargando…
Polymorphisms in MDM2 and TP53 Genes and Risk of Developing Therapy-Related Myeloid Neoplasms
One of the most severe complications after successful cancer therapy is the development of therapy-related myeloid neoplasms (t-MN). Constitutional genetic variation is likely to impact on t-MN risk. We aimed to evaluate if polymorphisms in the p53 pathway can be useful for predicting t-MN susceptib...
Autores principales: | Cabezas, Maria, García-Quevedo, Lydia, Alonso, Cintia, Manubens, Marta, Álvarez, Yolanda, Barquinero, Joan Francesc, Ramón y Cajal, Santiago, Ortega, Margarita, Blanco, Adoración, Caballín, María Rosa, Armengol, Gemma |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336808/ https://www.ncbi.nlm.nih.gov/pubmed/30655613 http://dx.doi.org/10.1038/s41598-018-36931-x |
Ejemplares similares
-
MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014) -
Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations
por: Fang, Shenying, et al.
Publicado: (2010) -
A New Model of Biodosimetry to Integrate Low and High Doses
por: Pujol, Mònica, et al.
Publicado: (2014) -
Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015) -
Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma
por: Ognjanovic, Simona, et al.
Publicado: (2012)